A share price of Regeneron Pharmaceuticals, Inc [REGN] is currently trading at $674.55, up 3.03%. An important factor to consider is whether the stock is rising or falling in short-term value. The REGN shares have gain 7.41% over the last week, with a monthly amount glided 20.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] stock has seen the most recent analyst activity on August 14, 2025, when Rothschild & Co Redburn initiated its Buy rating and assigned the stock a price target of $890. Previously, Argus downgraded its rating to Hold on June 30, 2025. On May 30, 2025, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $580 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform but stick to its price target of $662 on May 30, 2025. Citigroup upgraded its rating to a Buy but $700 remained the price target by the analyst firm on May 14, 2025. In a note dated February 05, 2025, Leerink Partners upgraded an Outperform rating on this stock and boosted its target price from $762 to $834.
Regeneron Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $476.49 and $834.42. Currently, Wall Street analysts expect the stock to reach $712 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $674.55 at the most recent close of the market. An investor can expect a potential return of 5.55% based on the average REGN price forecast.
Analyzing the REGN fundamentals
Trailing Twelve Months sales for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] were 14.25B which represents 0.90% growth. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.36%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.15 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 658.51 points at the first support level, and at 642.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 683.46, and for the 2nd resistance point, it is at 692.37.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] is 4.06. On the other hand, the Quick Ratio is 3.33, and the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 4.98, the price to book ratio is 2.29 and price to earnings (TTM) ratio is 16.15.
Transactions by insiders
Recent insider trading involved Pitofsky Jason, VP Controller, that happened on Nov 07 ’25 when 431.0 shares were sold. Officer, Jason Pitofsky completed a deal on Nov 07 ’25 to buy 431.0 shares. Meanwhile, Director POON CHRISTINE A sold 6500.0 shares on Oct 29 ’25.
